Could it be that this type of complete nonsense has been pushing the price lower?
Daily Trade Flow Review for Onyx Pharmaceuticals
Posted on 10/26/2012 by Allen Bersch
NEW YORK (AVAFIN) -- A record number of Onyx Pharmaceuticals call contracts were traded during the busy trading session. There were 1.3 call contracts traded for each put contract yielding a 0.79 put/call ratio where 4,680 put and 5,960 call contracts exchanged hands.
The skewed options ratio suggests that traders are re-balancing their portfolios in anticipation of a price shift. Unusual volume activity directly reflects investor outlook and confirms that a stock move is imminent.
With its minimal in-house R&D capabilities, Onyx could be left empty-handed if competitors demonstrate superior efficacy to Nexavar or Kyprolis fails to penetrate the global market. Additionaly, Nexavar yielded disappointing Phase III trial results in both lung cancer and metastatic melanoma, raising doubt about its ability to treat a wide array of cancers.
ONXX is trading below the 50 day moving average and higher than the 200 day moving average. Onyx Pharmaceuticals opened at $81.97 and the stock price declined $2.09 (2.55%) to $79.89 during the market session. ONXX is trading between the range of $78.01 - $82.47. Performance indicators show that the stock has lost -0.65% within the last month.
Yes that is an absurd report. The lung cancer trial was considered a long shot so nobody was counting on its success as part of their evaluation of ONXX. The failed trial won't affect Nexavar sales in HCC as it was a trial to see if Nexavar's efficacy could be improved if it was used in combination with another drug. Actually, I expect to see Nexavar's sales continue to increase as due to growth in Asia, which is the largest Nexavar market.